Calibr-Skaggs, AbbVie to develop cell therapies for solid tumours, autoimmune diseases
Under the expanded collaboration, both firms will further explore Calibr-Skaggs’ switchable CAR-T platform to develop cell therapy candidates…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Feb 24
Under the expanded collaboration, both firms will further explore Calibr-Skaggs’ switchable CAR-T platform to develop cell therapy candidates…
05 Feb 24
Inmagene has obtained an exclusive, worldwide and royalty-bearing license for the two drug candidates to further develop, manufacture…
01 Feb 24
Rusfertide is an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, which is currently in the…
29 Jan 24
APP13007 is designed to teat inflammation and pain post-ocular surgery and is undergoing evaluation by the US Food…
24 Jan 24
OpCT-001 is the lead cell therapy candidate being developed under the strategic R&D agreement that was formed in…
24 Jan 24
Under the partnership, both entities will use GenEdit's NanoGalaxy platform to explore and advance innovative nanoparticles, facilitating the…
19 Jan 24
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally
18 Jan 24
Along with istaroxime, the agreement licences Windtree’s preclinical next-generation SERCA2a activators, called dual mechanism SERCA2a activators
11 Jan 24
WuXi Biologics will grant exclusive rights to the investigational monoclonal antibodies to BioNTech in exchange for an upfront…
08 Jan 24
The products covered by the agreement are Ascendis Pharma's Skytrofa (lonapegsomatropin), a weekly injectable paediatric human growth hormone…